Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The general aim of this study is to investigate the efficacy and safety of afatinib alone and
in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy
within this trial) as treatment in patients with HER2-overexpressing, locally advanced or
metastatic inflammatory breast cancer. The study will include patients who have and have not
failed prior trastuzumab treatment.